Trials / Completed

CompletedNCT00795769

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 49 (actual)

Sponsor: Fred Hutchinson Cancer Center · Academic / Other
Sex: All
Age: 21 Years
Healthy volunteers: Not accepted

Summary

RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients undergoing stem cell transplant.

Detailed description

OBJECTIVES: I. To determine whether the incidence of nausea and vomiting related to administration of autologous hematopoetic stem cells cryopreserved in DMSO can be reduced by the use of a single dose of intravenous ondansetron prior to the stem cell infusion. II. To determine the number of patients who experience nausea and vomiting. OUTLINE: Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.

Conditions

Interventions

Type	Name	Description
DRUG	ondansetron	Given IV
OTHER	survey administration	Correlative studies
PROCEDURE	management of therapy complications	Ondansetron IV

Timeline

Start date: 2008-08-08
Primary completion: 2009-06-09
Completion: 2009-06-10
First posted: 2008-11-21
Last updated: 2017-05-23
Results posted: 2017-05-23

Locations

1 site across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT00795769. Inclusion in this directory is not an endorsement.